Why the study?
Does intraperitoneal administration of cefoperazone result in adequate systemic serum levels compared to intravenous administration in patients undergoing continuous ambulatory peritoneal dialysis?
Does intraperitoneal administration of cefoperazone result in adequate systemic serum levels compared to intravenous administration in patients undergoing continuous ambulatory peritoneal dialysis?
Intraperitoneal administration of cefoperazone in CAPD patients provides high systemic availability (95%) and adequate serum levels for treating systemic bacterial infections.
Supports intraperitoneal cefoperazone for systemic infections in CAPD patients; confirms high systemic availability and extends dosing options beyond IV.
Serum cefoperazone (CFP) kinetics after a 1-gm dose added to the peritoneal dialysate were followed in seven patients undergoing continuous ambulatory peritoneal dialysis (CAPD). In a randomized order five of the seven patients received 1 gm IV CFP. Serum samples were collected over 10 hr during one dialysate exchange interval. CFP concentrations were determined by HPLC. After intravenous dosing CFP mean peak and 6-hr serum concentrations were 104.2 +/- 29.1 micrograms X ml-1 and 8.5 +/- 3.8 micrograms X ml-1, mean body clearance was 80 +/- 20 ml X min-1, and mean apparent volume of distribution was 14.6 +/- 3.2 l. The elimination rate constant (kel) varied from 0.29 to 0.38 hr-1 and was almost identical to kel derived from intraperitoneal application (range 0.29 to 0.42 hr-1). Instillation of CFP with the peritoneal dialysate resulted in a rapid rise of serum levels (Tmax = 1.9 +/- 0.7 hr; absorption rate constant ka = 0.68 +/- 0.11 hr-1), and sufficient CFP concentrations (Cmax = 33.2 +/- 5.3 micrograms X ml-1), were maintained over 6 hr (C6 hr = 17.3 +/- 5.8 micrograms X ml-1). Mean systemic availability of intraperitoneal CFP was 95% +/- 12%. Intraperitoneal administration of CFP in patients undergoing CAPD resulted in serum levels of CFP adequate for systemic treatment of bacterial infections.
No takes yet. Share an insight, caveat, or question.
Keller et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: